[1] CHAR W,LESLIE R. Treatment of venous thromboembolism in pediatric patients[J]. Blood, 2020,135(5): 335-343.
[2] PAUL M,ELIZABETH C,ANTHONY C,et al. Antithrombotic therapy in neonates and children: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines.[J]. Chest, 2012.141(Suppl 2):e737S-e801S.
[3] ROSSANO J W, CABRERA A G, JEFFERIES J L, et al. Pediatric cardiac intensive care society 2014 consensus statement[J]. Pediatr Crit Care Med, 2016, 17:S20-S34.
[4] MAHAJERIN A, PETTY J K, HANSON S J, et al. Prophylaxis against venous thromboembolism in pediatric trauma: A practice management guideline from the Eastern Association for the Surgery of Trauma and the Pediatric Trauma Society[J].J Trauma Acute Care Surg, 2017, 82(3):627-636.
[5] American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism[J]. Blood Adv, 2018,2(22):3292-3316.
[6] MORGAN J, CHECKETTS M, ARANA A, et al. Prevention of perioperative venous thromboembolism in pediatric patients: Guidelines from the Association of PaediatricAnaesthetists of Great Britain and Ireland(APAGBI)[J]. Pediatric Anesthesia, 2018, 28(5):382-391.
[7] SIBSON K R, BISS T T, FURNESS C L, et al. BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy[J]. Br J Haematol, 2018, 180(4):511-525.
[8] HALTON J M L, ALBISETTI M, BISS B, et al. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability[J]. J Thromb Haemost, 2017, 15(11):2147-2157. doi: 10.1111/jth.13847.
[9] HALTON J M L, PICARD A C, HARPER R, et al. Pharmacokinetics, pharmacodynamics, safety and tolerability of dabigatran etexilate oral liquid formulation in infants with venous thromboembolism[J]. Thromb Haemost, 2017, 117(11): 2168-2175.
[10] HALTON J, BRANDÃO L R, LUCIANI M, et al.Dabigatran etexilate for the treatment of acute venous thromboembolism in children(DIVERSITY): a randomised, controlled, open-label, phase 2b/3, non-inferiority trial[J]. Lancet Haematol, 2021, 8(1):e22-e33.
[11] ALBISETTI M,BRANDAO L, BOMGAARS L, et al. Efficacy and safety of dabigatran etexilate for treatment of venous thromboembolism in paediatric patients-results of the DIVERSITY trial[J]. Res Pract Thromb Haemost, 2019,03(S1):139-140.
[12] LEONARDO R, BRAND O, MANUELA A, et al. Safety of dabigatran etexilate for the secondary prevention of venous thromboembolism in children[J]. Blood, 2020,135(7):491-504.
[13] European Medicines Agency. Committee for medicinal products for human use(CHMP). Minutes for the meeting on 09-12 November 2020. Pradaxa - dabigatran etexilate - EMEA/H/C/000829/X/0122/G[EB/OL]. https://www.ema.europa.eu/en/documents/minutes/minutes-chmp-meeting-9-12-november-2020_en.pdf[2021-01-05](2021.3.23)
[14] MALE C, LENSING A W A, PALUMBO J S, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial[J]. Lancet Haematol, 2020,7(1):e18-e27.
[15] MONAGLEP, LENSING A W A, THELEN K, et al. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism(EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies[J]. Lancet Haematol, 2019,6(10):e500-e509.
[16] MALE C, LENSING A W A, PALUMBO J S. EINSTEIN-Jr Phase 3 Investigators. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial[J]. Lancet Haematol, 2020, 7(1):e18-e27.
[17] European Medicines Agency. European Medicines Agency decision [EB/OL]. [2019-04-17]. https://www.ema.europa.eu/en/documents/pip-decision/p/0126/2019-ema-decision-17-april-2019-acceptance-modification-agreed-paediatric-investigation-plan_ en.pdf.
[18] Center For Drug Evaluation,NMPA. Publicity of drug priority review. Acceptance No: JXHS2000148/9 [EB/OL]. [2021-03-23]. http://www.cde.org.cn/news.do?method= changePage&pageName=service&frameStr=21#
[19] Daiichi Sankyo, Inc.Edoxaban for prevention of blood vessels being vlocked by clots(thrombotic events) in children at risk because of cardiac disease[EB/OL]. [2021-03-23]. https://clinicaltrials.gov/ct2/show/NCT03395639.
[20] SankyoDaiichi,Inc. Hokusai study in pediatric patients withconfirmed venous thromboembolism(VTE)[EB/OL]. [2021-03-23]. https://clinicaltrials.gov/ct2/show/NCT02798471.
[21] VANOMMEN C H, ALBISETTI M, CHAN A K, et al. The Edoxaban Hokusai VTE pediatricsstudy: An open-label, multicenter, randomized study of edoxaban for pediatric venous thromboembolic disease[J]. Res Pract Thromb Haemost, 2020,4(5):886-892. Doi:10.1002/rth2.12352.
[22] Bristol-Myers Squibb,A study of the safety and effectiveness of apixaban in preventing blood clots in children with leukemia who have a central venous catheter and are treated with asparaginase[EB/OL]. [2021-03-23]. https://clinicaltrials.gov/ct2/show/NCT02369653.
[23] New York Medical College. Oral anticoagulant apixaban for treatment of venous thromboembolism(VTE)[EB/OL]. [2021-03-23]. https://clinicaltrials.gov/ct2/show/NCT04041843.
[24] Pfizer, Apixaban for the acute treatment of venous thromboembolism in children[EB/OL]. [2021-03-23]. https://clinicaltrials.gov/ct2/show/NCT02464969
[25] Food and Drug Administration. FDA approved betrixaban (BEVYXXA, Portola) for the prophylaxis of venous thromboembolism (VTE) in adult patients [EB/OL]. [2017-10-26]. www.fda.gov/drugs/informationondrugs/approveddrugs/ucm564422.htm.
[26] MONAGLE P,CUELLO C A,AUGUSTINE C,et al. American Society of Hematology 2018 guidelinesfor management of venous thromboembolism:treatment of pediatric venous thromboembolism[J]. Blood Adv,2018,2(22):3292-3316.
[27] MAHAJERIN A,CROTEAU S E. Epidemiology and risk assessment of pediatric venous thromboembolism [J]. Front Pediatr,2017, Doi: 10.3389/fped.2017.00068.
[28] GOLDENBERG N A, KITTELSON J M, ABSHIRE T C, et al. Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism the Kids-DOTT randomized clinical trial[J]. JAMA,2022,327(2):129-137.